– Third-Quarter Revenue of $1.03 Billion
–
– Third-Quarter GAAP Earnings per Share of
$1.69 and Non-GAAP Earnings per Share of $2.72 –
– Updates 2023 Guidance –
Charles River Laboratories International, Inc. (NYSE: CRL) today
reported its results for the third quarter of 2023. For the
quarter, revenue was $1.03 billion, an increase of 3.8% from $989.2
million in the third quarter of 2022.
Acquisitions contributed 0.2% to consolidated third-quarter
revenue growth. The impact of foreign currency translation
benefited reported revenue growth by 1.4%. The divestiture of the
Avian Vaccine business in December 2022 reduced reported revenue
growth by 1.9%. Excluding the effect of these items, organic
revenue growth of 4.1% was driven primarily by the Discovery and
Safety Assessment (DSA) and the Research Models and Services (RMS)
business segments.
On a GAAP basis, third-quarter net income attributable to common
shareholders was $87.4 million, a decrease of 9.4% from $96.5
million for the same period in 2022. Third-quarter diluted earnings
per share on a GAAP basis were $1.69, a decrease of 10.1% from
$1.88 for the third quarter of 2022. The lower GAAP net income and
earnings per share were driven primarily by site consolidation and
associated costs, as well as non-operating items, including a loss
on certain venture capital and other strategic investments,
increased interest expense, and a higher tax rate. GAAP earnings
per share included a loss from the Company’s certain venture
capital and other strategic investments of $0.11 per share in the
third quarter of 2023, compared to a gain of $0.04 per share for
the same period in 2022. Certain venture capital and other
strategic investment performance has been excluded from the
Company’s non-GAAP results.
On a non-GAAP basis, net income was $140.5 million for the third
quarter of 2023, an increase of 4.2% from $134.7 million for the
same period in 2022. Third-quarter diluted earnings per share on a
non-GAAP basis were $2.72, an increase of 3.4% from $2.63 per share
for the third quarter of 2022. The non-GAAP net income and earnings
per share increases were driven primarily by higher revenue and
operating income, partially offset by increased interest expense
and a higher tax rate.
James C. Foster, Chairman, President and Chief Executive
Officer, said, “We were pleased that our third-quarter financial
results exceeded our expectations, and that some early signs of
more favorable demand trends began to emerge, such as a sequential
improvement in the Safety Assessment cancellation rate. However, we
also experienced continued pressure from current client spending
patterns, which began to have a discernable impact on the RMS
segment and our Microbial Solutions business in the third
quarter.”
“We believe our business model is resilient, and will benefit
from our efforts to ensure that our cost structure remains aligned
with the current pace of demand. We remain guided by the
imperatives that differentiate us: Strengthening our unique
portfolio, enhancing our scientific expertise, providing
outstanding client service, and driving greater operating
efficiencies. In this market environment, we will focus on market
share and our unique role in the drug discovery and non-clinical
development process to further distinguish ourselves. We believe
this will increasingly enable clients to choose to partner with
Charles River to derive additional value through our flexible and
efficient outsourcing solutions,” Mr. Foster concluded.
Third-Quarter Segment
Results
Research Models and Services (RMS)
Revenue for the RMS segment was $186.8 million in the third
quarter of 2023, an increase of 3.7% from $180.1 million in the
third quarter of 2022. The impact of foreign currency translation
benefited revenue by 0.5% in the quarter. Organic revenue growth of
3.2% was primarily driven by research model services, particularly
the Insourcing Solutions (IS) business. Revenue growth for small
research models in all geographic regions also contributed,
principally driven by increased pricing. This was partially offset
by lower revenue growth in the Cell Solutions business and the
timing of large research model shipments within China.
In the third quarter of 2023, the RMS segment’s GAAP operating
margin decreased to 15.2% from 19.9% in the third quarter of 2022,
and on a non-GAAP basis, the operating margin decreased to 18.9%
from 23.5%. The GAAP and non-GAAP operating margin decreases were
driven primarily by the revenue mix and reduced operating leverage
from lower revenue growth, as well as the timing of large model
shipments within China.
Discovery and Safety Assessment (DSA)
Revenue for the DSA segment was $664.0 million in the third
quarter of 2023, an increase of 7.2% from $619.5 million in the
third quarter of 2022. The impact of foreign currency translation
benefited revenue by 1.5%, and the SAMDI Tech acquisition
contributed 0.4% to reported DSA revenue growth in the quarter.
Organic revenue growth of 5.3% was driven by the Safety Assessment
business, primarily as a result of higher pricing and increased
study volume.
In the third quarter of 2023, the DSA segment’s GAAP operating
margin decreased to 22.1% from 22.9% in the third quarter of 2022.
The decrease in the GAAP operating margin was primarily
attributable to site consolidation, impairment, and associated
costs related to the closure of a small Discovery Services site in
California. On a non-GAAP basis, the operating margin increased to
27.2% from 26.2% in the third quarter of 2022. The non-GAAP
operating margin improvement was primarily driven by operating
leverage from higher revenue in the Safety Assessment business.
Manufacturing Solutions (Manufacturing)
Revenue for the Manufacturing segment was $175.7 million in the
third quarter of 2023, a decrease of 7.3% from $189.6 million in
the third quarter of 2022. The impact of the Avian Vaccine
divestiture reduced revenue by 9.9%. The impact of foreign currency
translation benefited revenue by 1.7% in the quarter. Organic
revenue growth of 0.9% reflected higher revenue in the CDMO
business, which was almost entirely offset by lower revenue in the
Biologics Testing Solutions and Microbial Solutions businesses.
In the third quarter of 2023, the Manufacturing segment’s GAAP
operating margin decreased to 15.0% from 16.6% in the third quarter
of 2022, and on a non-GAAP basis, the operating margin decreased to
24.5% from 28.6% in the third quarter of 2022. The GAAP and
non-GAAP operating margin declines were driven by each of the
Manufacturing segment’s businesses.
Updates 2023 Guidance
The Company is updating its 2023 financial guidance, which was
previously provided on August 9, 2023. As it moves into the fourth
quarter, the Company is narrowing its revenue growth and non-GAAP
earnings per share ranges. The updates principally reflect a shift
in the gating of the financial results in the second half of the
year, as demonstrated by the third-quarter financial performance
that exceeded the Company’s prior expectations.
The Company’s 2023 guidance for revenue growth and earnings per
share is as follows:
2023 GUIDANCE
CURRENT
PRIOR
Revenue growth, reported
2.5% – 3.5%
2.5% – 4.5%
Impact of divestitures/(acquisitions),
net
~1.5%
~1.5%
Impact of 53rd week in 2022
~1.5%
~1.5%
Unfavorable/(favorable) impact of foreign
exchange
0.0% - (0.5)%
0.0% - (0.5)%
Revenue growth, organic (1)
5.5% – 6.5%
5.5% – 7.5%
GAAP EPS estimate
$7.30 – $7.50
$7.60 – $8.20
Acquisition-related amortization
$2.00 – $2.05
~$2.00
Acquisition and integration-related
adjustments (2)
~$0.25
$0.20 – $0.25
Costs associated with restructuring
actions (3)
$0.30 – $0.35
~$0.10
Certain venture capital and other
strategic investment losses/(gains), net (4)
$0.18
$0.06
Other items (5)
~$0.40
~$0.30
Non-GAAP EPS estimate
$10.50 – $10.70
$10.30 – $10.90
Footnotes to
Guidance Table:
(1) Organic revenue growth is defined as
reported revenue growth adjusted for completed acquisitions and
divestitures, the 53rd week in 2022, and foreign currency
translation.
(2) These adjustments are related to the
evaluation and integration of acquisitions and divestitures, and
primarily include transaction, advisory, certain third-party
integration costs, and certain costs associated with
acquisition-related efficiency initiatives.
(3) These adjustments primarily include
site consolidation, severance, impairment, and other costs related
to the Company’s restructuring actions.
(4) Certain venture capital and other
strategic investment performance only includes recognized gains or
losses on certain investments. The Company does not forecast the
future performance of these investments.
(5) These items primarily relate to
charges associated with U.S. and international tax legislation that
necessitated changes to the Company’s international financing
structure; and certain third-party legal costs related to (a)
environmental litigation related to the Microbial Solutions
business and (b) investigations by the U.S. government into the NHP
supply chain related to our Safety Assessment business.
Webcast
Charles River has scheduled a live webcast on Wednesday,
November 8th, at 8:30 a.m. ET to discuss matters relating to this
press release. To participate, please go to ir.criver.com and
select the webcast link. You can also find the associated slide
presentation and reconciliations of GAAP financial measures to
non-GAAP financial measures on the website.
Non-GAAP Reconciliations
The Company reports non-GAAP results in this press release,
which exclude often-one-time charges and other items that are
outside of normal operations. A reconciliation of GAAP to non-GAAP
results is provided in the schedules at the end of this press
release.
Use of Non-GAAP Financial
Measures
This press release contains non-GAAP financial measures, such as
non-GAAP earnings per diluted share, non-GAAP operating income,
non-GAAP operating margin, and non-GAAP net income. Non-GAAP
financial measures exclude, but are not limited to, the
amortization of intangible assets, and other charges and
adjustments related to our acquisitions and divestitures, including
the gain on our sale of our Avian Vaccine business; expenses
associated with evaluating and integrating acquisitions and
divestitures, including advisory fees and certain other
transaction-related costs, as well as fair value adjustments
associated with contingent consideration; charges, gains, and
losses attributable to businesses or properties we plan to close,
consolidate, or divest; severance and other costs associated with
our efficiency initiatives; the write-off of deferred financing
costs and fees related to debt financing; investment gains or
losses associated with our venture capital and other strategic
equity investments; certain legal costs in our Microbial Solutions
business related to environmental litigation and in our Safety
Assessment business related to U.S. government investigations into
the NHP supply chain; and adjustments related to the recognition of
deferred tax assets expected to be utilized as a result of changes
to the our international financing structure and the revaluation of
deferred tax liabilities as a result of foreign tax legislation.
This press release also refers to our revenue on both a GAAP and
non-GAAP basis: “organic revenue growth,” which we define as
reported revenue growth adjusted for foreign currency translation,
acquisitions, divestitures, and the impact of the 53rd week in
2022. We exclude these items from the non-GAAP financial measures
because they are outside our normal operations. There are
limitations in using non-GAAP financial measures, as they are not
presented in accordance with generally accepted accounting
principles, and may be different than non-GAAP financial measures
used by other companies. In particular, we believe that the
inclusion of supplementary non-GAAP financial measures in this
press release helps investors to gain a meaningful understanding of
our core operating results and future prospects without the effect
of these often-one-time charges, and is consistent with how
management measures and forecasts the Company's performance,
especially when comparing such results to prior periods or
forecasts. We believe that the financial impact of our acquisitions
and divestitures (and in certain cases, the evaluation of such
acquisitions and divestitures, whether or not ultimately
consummated) is often large relative to our overall financial
performance, which can adversely affect the comparability of our
results on a period-to-period basis. In addition, certain
activities and their underlying associated costs, such as business
acquisitions, generally occur periodically but on an unpredictable
basis. We calculate non-GAAP integration costs to include
third-party integration costs incurred post-acquisition. Presenting
revenue on an organic basis allows investors to measure our revenue
growth exclusive of acquisitions, divestitures, the 53rd week in
2022, and foreign currency exchange fluctuations more clearly.
Non-GAAP results also allow investors to compare the Company’s
operations against the financial results of other companies in the
industry who similarly provide non-GAAP results. The non-GAAP
financial measures included in this press release are not meant to
be considered superior to or a substitute for results of operations
presented in accordance with GAAP. The Company intends to continue
to assess the potential value of reporting non-GAAP results
consistent with applicable rules and regulations. Reconciliations
of the non-GAAP financial measures used in this press release to
the most directly comparable GAAP financial measures are set forth
in this press release, and can also be found on the Company’s
website at ir.criver.com.
Caution Concerning Forward-Looking
Statements
This press release includes forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements may be identified by the use of
words such as “anticipate,” “believe,” “expect,” “intend,” “will,”
“would,” “may,” “estimate,” “plan,” “outlook,” and “project,” and
other similar expressions that predict or indicate future events or
trends or that are not statements of historical matters. These
statements also include statements regarding Charles River’s
expectations regarding the availability of Cambodia-sourced NHPs;
the impact of the investigations by the U.S. Department of Justice
into the Cambodia NHP supply chain, including but not limited to
Charles River’s ability to cooperate fully with the U.S.
government; Charles River’s ability to effectively manage any
Cambodia NHP supply impact; the projected future financial
performance of Charles River and our specific businesses, including
our expectations with respect to the impact of NHP supply
constraints; earnings per share; client demand, particularly the
future demand for drug discovery and development products and
services, including our expectations for future revenue trends; our
expectations with respect to pricing of our products and services;
our expectations with respect to future tax rates and the impact of
such tax rates on our business; our expectations with respect to
the impact of acquisitions and divestitures completed in 2021,
2022, and 2023 on the Company, our service offerings, client
perception, strategic relationships, revenue, revenue growth rates,
revenue growth drivers, and earnings; the development and
performance of our services and products, including our investments
in our portfolio; market and industry conditions including the
outsourcing of services and identification of spending trends by
our clients and funding available to them; and Charles River’s
future performance as delineated in our forward-looking guidance,
and particularly our expectations with respect to revenue, the
impact of foreign exchange, interest rates, enhanced efficiency
initiatives. Forward-looking statements are based on Charles
River’s current expectations and beliefs, and involve a number of
risks and uncertainties that are difficult to predict and that
could cause actual results to differ materially from those stated
or implied by the forward-looking statements. Those risks and
uncertainties include, but are not limited to: NHP supply
constraints and the investigations by the U.S. Department of
Justice, including the impact on our projected future financial
performance, the timing of the resumption of Cambodia NHP imports,
our ability to manage supply impact, and potential study delays in
our Safety Assessment business attributable to NHP supply
constraints; changes and uncertainties in the global economy and
financial markets; the ability to successfully integrate businesses
we acquire; the timing and magnitude of our share repurchases;
negative trends in research and development spending, negative
trends in the level of outsourced services, or other cost reduction
actions by our clients; the ability to convert backlog to revenue;
special interest groups; contaminations; industry trends; new
displacement technologies; USDA and FDA regulations; changes in
law; continued availability of products and supplies; loss of key
personnel; interest rate and foreign currency exchange rate
fluctuations; changes in tax regulation and laws; changes in
generally accepted accounting principles; disruptions in the global
economy caused by the ongoing conflict between the Russian
federation and Ukraine; and any changes in business, political, or
economic conditions due to the threat of future terrorist activity
in the U.S. and other parts of the world, and related U.S. military
action overseas. A further description of these risks,
uncertainties, and other matters can be found in the Risk Factors
detailed in Charles River's Annual Report on Form 10-K as filed on
February 22, 2023, as well as other filings we make with the
Securities and Exchange Commission. Because forward-looking
statements involve risks and uncertainties, actual results and
events may differ materially from results and events currently
expected by Charles River, and Charles River assumes no obligation
and expressly disclaims any duty to update information contained in
this press release except as required by law.
About Charles River
Charles River provides essential products and services to help
pharmaceutical and biotechnology companies, government agencies and
leading academic institutions around the globe accelerate their
research and drug development efforts. Our dedicated employees are
focused on providing clients with exactly what they need to improve
and expedite the discovery, early-stage development and safe
manufacture of new therapies for the patients who need them. To
learn more about our unique portfolio and breadth of services,
visit www.criver.com.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
SCHEDULE 1 CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(UNAUDITED) (in thousands, except for per share data)
Three Months Ended Nine Months Ended
September 30, 2023 September 24, 2022 September
30, 2023 September 24, 2022 Service revenue
$
869,759
$
812,894
$
2,602,016
$
2,316,206
Product revenue
156,864
176,263
513,917
560,011
Total revenue
1,026,623
989,157
3,115,933
2,876,217
Costs and expenses: Cost of services provided (excluding
amortization of intangible assets)
587,560
530,706
1,731,136
1,540,193
Cost of products sold (excluding amortization of intangible assets)
77,223
88,228
246,326
272,257
Selling, general and administrative
176,109
183,714
550,713
465,458
Amortization of intangible assets
34,229
35,533
103,419
111,144
Operating income
151,502
150,976
484,339
487,165
Other income (expense): Interest income
1,373
122
3,605
437
Interest expense
(33,742)
(11,375)
(103,166)
(24,512)
Other expense, net
(6,260)
(16,616)
(12,200)
(85,024)
Income before income taxes
112,873
123,107
372,578
378,066
Provision for income taxes
24,852
25,495
81,160
74,564
Net income
88,021
97,612
291,418
303,502
Less: Net income attributable to noncontrolling interests
632
1,139
3,878
4,686
Net income attributable to common shareholders
$
87,389
$
96,473
$
287,540
$
298,816
Earnings per common share Net income attributable to common
shareholders: Basic
$
1.70
$
1.90
$
5.62
$
5.88
Diluted
$
1.69
$
1.88
$
5.58
$
5.83
Weighted-average number of common shares outstanding: Basic
51,283
50,870
51,199
50,778
Diluted
51,607
51,283
51,493
51,285
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
SCHEDULE 2 CONDENSED CONSOLIDATED BALANCE SHEETS
(UNAUDITED) (in thousands, except per share amounts)
September 30, 2023 December 31, 2022
Assets Current assets: Cash and cash equivalents
$
157,174
$
233,912
Trade receivables and contract assets, net of allowances for credit
losses of $21,187 and $11,278, respectively
799,310
752,390
Inventories
292,972
255,809
Prepaid assets
101,555
89,341
Other current assets
93,314
107,580
Total current assets
1,444,325
1,439,032
Property, plant and equipment, net
1,525,485
1,465,655
Venture capital and strategic equity investments
301,847
311,602
Operating lease right-of-use assets, net
375,322
391,762
Goodwill
2,884,602
2,849,903
Intangible assets, net
886,286
955,275
Deferred tax assets
34,264
41,262
Other assets
154,876
148,279
Total assets
$
7,607,007
$
7,602,770
Liabilities, Redeemable Noncontrolling Interests and
Equity Current liabilities: Accounts payable
136,341
205,915
Accrued compensation
224,183
197,078
Deferred revenue
250,485
264,259
Accrued liabilities
198,062
219,758
Other current liabilities
184,745
204,575
Total current liabilities
993,816
1,091,585
Long-term debt, net and finance leases
2,514,217
2,707,531
Operating lease right-of-use liabilities
390,437
389,745
Deferred tax liabilities
185,310
215,582
Other long-term liabilities
172,518
174,822
Total liabilities
4,256,298
4,579,265
Redeemable noncontrolling interest
39,948
42,427
Equity: Preferred stock, $0.01 par value; 20,000 shares authorized;
no shares issued and outstanding
—
—
Common stock, $0.01 par value; 120,000 shares authorized; 51,400
shares issued and 51,296 shares outstanding as of September 30,
2023, and 50,944 shares issued and outstanding as of December 31,
2022
514
509
Additional paid-in capital
1,877,120
1,804,940
Retained earnings
1,720,441
1,432,901
Treasury stock, at cost, 104 and zero shares, as of September 30,
2023 and December 31, 2022, respectively
(24,016)
—
Accumulated other comprehensive loss
(268,066)
(262,057)
Total equity attributable to common shareholders
3,305,993
2,976,293
Noncontrolling interests (nonredeemable)
4,768
4,785
Total equity
3,310,761
2,981,078
Total liabilities, redeemable noncontrolling interests and equity
$
7,607,007
$
7,602,770
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
SCHEDULE 3 CONDENSED CONSOLIDATED STATEMENTS OF CASH
FLOWS (UNAUDITED) (in thousands) Nine Months
Ended September 30, 2023 September 24, 2022
Cash flows relating to operating activities Net income
$
291,418
$
303,502
Adjustments to reconcile net income to net cash provided by
operating activities: Depreciation and amortization
233,610
226,325
Stock-based compensation
52,527
51,548
Loss on debt extinguishment and amortization of other financing
costs
2,975
3,054
Deferred income taxes
(28,251)
(26,323)
Loss on venture capital and strategic equity investments, net
9,246
20,068
Long-lived asset impairment charges
26,202
—
Loss on divestitures, net
995
—
Changes in fair value of contingent consideration arrangements
1,810
(15,420)
Other, net
13,192
31,574
Changes in assets and liabilities: Trade receivables and contract
assets, net
(59,081)
(174,169)
Inventories
(44,126)
(76,283)
Accounts payable
(26,531)
5,979
Accrued compensation
28,438
(32,734)
Deferred revenue
(9,997)
53,565
Customer contract deposits
(21,534)
16,234
Other assets and liabilities, net
(7,938)
(2,037)
Net cash provided by operating activities
462,955
384,883
Cash flows relating to investing activities Acquisition of
businesses and assets, net of cash acquired
(50,166)
(283,392)
Capital expenditures
(240,205)
(235,709)
Purchases of investments and contributions to venture capital
investments
(36,322)
(129,363)
Proceeds from sale of investments
3,953
3,104
Other, net
(2,044)
(6,945)
Net cash used in investing activities
(324,784)
(652,305)
Cash flows relating to financing activities Proceeds from
long-term debt and revolving credit facility
333,034
2,798,665
Proceeds from exercises of stock options
19,658
17,710
Payments on long-term debt, revolving credit facility, and finance
lease obligations
(530,909)
(2,524,387)
Purchase of treasury stock
(24,016)
(38,492)
Payments of contingent consideration
(2,711)
(10,356)
Purchases of additional equity interests, net
—
(30,533)
Other, net
(4,145)
(6,048)
Net cash provided by (used in) financing activities
(209,089)
206,559
Effect of exchange rate changes on cash, cash equivalents, and
restricted cash
(4,680)
10,726
Net change in cash, cash equivalents, and restricted cash
(75,598)
(50,137)
Cash, cash equivalents, and restricted cash, beginning of period
241,214
246,314
Cash, cash equivalents, and restricted cash, end of period
$
165,616
$
196,177
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
SCHEDULE 4 RECONCILIATION OF GAAP TO NON-GAAP
SELECTED BUSINESS SEGMENT INFORMATION (UNAUDITED)(1) (in
thousands, except percentages) Three Months Ended
Nine Months Ended September 30, 2023 September 24,
2022 September 30, 2023 September 24, 2022
Research Models and Services Revenue
$
186,848
$
180,114
$
596,562
$
543,066
Operating income
28,326
35,891
117,653
123,299
Operating income as a % of revenue
15.2 %
19.9 %
19.7 %
22.7 %
Add back: Amortization related to acquisitions
5,398
5,467
16,383
14,777
Severance
965
(110)
965
1,017
Acquisition related adjustments (2)
604
1,126
2,431
2,480
Total non-GAAP adjustments to operating income
$
6,967
$
6,483
$
19,779
$
18,274
Operating income, excluding non-GAAP adjustments
$
35,293
$
42,374
$
137,432
$
141,573
Non-GAAP operating income as a % of revenue
18.9 %
23.5 %
23.0 %
26.1 %
Depreciation and amortization
$
13,872
$
13,128
$
41,310
$
35,825
Capital expenditures
$
9,192
$
10,743
$
35,769
$
33,239
Discovery and Safety Assessment Revenue
$
664,028
$
619,463
$
1,989,838
$
1,755,639
Operating income
146,819
142,143
479,788
375,922
Operating income as a % of revenue
22.1 %
22.9 %
24.1 %
21.4 %
Add back: Amortization related to acquisitions
17,749
20,039
52,980
63,253
Severance
2,001
(28)
2,001
433
Acquisition related adjustments (2)
630
(395)
3,233
(5,909)
Site consolidation costs, impairments and other items (3)
13,318
645
17,615
3,001
Total non-GAAP adjustments to operating income
$
33,698
$
20,261
$
75,829
$
60,778
Operating income, excluding non-GAAP adjustments
$
180,517
$
162,404
$
555,617
$
436,700
Non-GAAP operating income as a % of revenue
27.2 %
26.2 %
27.9 %
24.9 %
Depreciation and amortization
$
44,088
$
43,913
$
129,662
$
135,328
Capital expenditures
$
41,967
$
43,400
$
155,477
$
133,908
Manufacturing Solutions Revenue
$
175,747
$
189,580
$
529,533
$
577,512
Operating income
26,275
31,479
52,784
140,350
Operating income as a % of revenue
15.0 %
16.6 %
10.0 %
24.3 %
Add back: Amortization related to acquisitions
11,164
10,115
34,310
33,386
Severance
612
241
4,045
619
Acquisition related adjustments (2)
3,279
10,555
6,290
(4,191)
Site consolidation costs, impairments and other items (3)
1,700
1,741
11,312
3,681
Total non-GAAP adjustments to operating income
$
16,755
$
22,652
$
55,957
$
33,495
Operating income, excluding non-GAAP adjustments
$
43,030
$
54,131
$
108,741
$
173,845
Non-GAAP operating income as a % of revenue
24.5 %
28.6 %
20.5 %
30.1 %
Depreciation and amortization
$
20,070
$
17,005
$
59,677
$
53,487
Capital expenditures
$
14,349
$
18,137
$
46,949
$
65,396
Unallocated Corporate Overhead
$
(49,918)
$
(58,537)
$
(165,886)
$
(152,406)
Add back: Severance
—
(193)
—
1,061
Acquisition related adjustments (2)
1,958
1,229
8,960
8,359
Total non-GAAP adjustments to operating expense
$
1,958
$
1,036
$
8,960
$
9,420
Unallocated corporate overhead, excluding non-GAAP adjustments
$
(47,960)
$
(57,501)
$
(156,926)
$
(142,986)
Total Revenue
$
1,026,623
$
989,157
$
3,115,933
$
2,876,217
Operating income
151,502
150,976
484,339
487,165
Operating income as a % of revenue
14.8 %
15.3 %
15.5 %
16.9 %
Add back: Amortization related to acquisitions
34,311
35,621
103,673
111,416
Severance
3,578
(90)
7,011
3,130
Acquisition related adjustments (2)
6,471
12,515
20,914
739
Site consolidation costs, impairments and other items (3)
15,018
2,386
28,927
6,682
Total non-GAAP adjustments to operating income
$
59,378
$
50,432
$
160,525
$
121,967
Operating income, excluding non-GAAP adjustments
$
210,880
$
201,408
$
644,864
$
609,132
Non-GAAP operating income as a % of revenue
20.5 %
20.4 %
20.7 %
21.2 %
Depreciation and amortization
$
78,870
$
74,605
$
233,610
$
226,325
Capital expenditures
$
65,947
$
72,393
$
240,205
$
235,709
(1)
Charles River management believes that supplementary non-GAAP
financial measures provide useful information to allow investors to
gain a meaningful understanding of our core operating results and
future prospects, without the effect of often-one-time charges and
other items which are outside our normal operations, consistent
with the manner in which management measures and forecasts the
Company’s performance. The supplementary non-GAAP financial
measures included are not meant to be considered superior to, or a
substitute for results of operations prepared in accordance with
U.S. GAAP. The Company intends to continue to assess the potential
value of reporting non-GAAP results consistent with applicable
rules, regulations and guidance.
(2)
These adjustments are related to the evaluation and integration of
acquisitions, which primarily include transaction, third-party
integration, and certain compensation costs, fair value adjustments
associated with contingent consideration arrangments, and an
adjustment related to certain indirect tax liabilities.
(3)
Other items include certain third-party legal costs related to (a)
an environmental litigation related to the Microbial business and
(b) investigations by the U.S. government into the NHP supply chain
applicable to our Safety Assessment business.
CHARLES RIVER
LABORATORIES INTERNATIONAL, INC. SCHEDULE 5
RECONCILIATION OF GAAP EARNINGS TO NON-GAAP EARNINGS
(UNAUDITED)(1) (in thousands, except per share data)
Three Months Ended Nine Months Ended
September 30, 2023 September 24, 2022 September
30, 2023 September 24, 2022 Net income
attributable to common shareholders
$
87,389
$
96,473
$
287,540
$
298,816
Add back: Non-GAAP adjustments to operating income (Refer to
previous schedule)
59,378
50,432
160,525
121,967
Venture capital and strategic equity investment losses, net
7,249
(3,447)
12,404
20,068
Loss on divestitures (2)
433
—
995
—
Other (3)
—
240
495
4,205
Tax effect of non-GAAP adjustments: Non-cash tax provision related
to international financing structure (4)
1,283
1,161
3,703
3,624
Tax effect of the remaining non-GAAP adjustments
(15,271)
(10,115)
(43,929)
(30,928)
Net income attributable to common shareholders, excluding non-GAAP
adjustments
$
140,461
$
134,744
$
421,733
$
417,752
Weighted average shares outstanding - Basic
51,283
50,870
51,199
50,778
Effect of dilutive securities: Stock options, restricted stock
units and performance share units
324
413
294
507
Weighted average shares outstanding - Diluted
51,607
51,283
51,493
51,285
Earnings per share attributable to common shareholders:
Basic
$
1.70
$
1.90
$
5.62
$
5.88
Diluted
$
1.69
$
1.88
$
5.58
$
5.83
Basic, excluding non-GAAP adjustments
$
2.74
$
2.65
$
8.24
$
8.23
Diluted, excluding non-GAAP adjustments
$
2.72
$
2.63
$
8.19
$
8.15
(1)
Charles River management believes that supplementary non-GAAP
financial measures provide useful information to allow investors to
gain a meaningful understanding of our core operating results and
future prospects, without the effect of often-one-time charges and
other items which are outside our normal operations, consistent
with the manner in which management measures and forecasts the
Company’s performance. The supplementary non-GAAP financial
measures included are not meant to be considered superior to, or a
substitute for results of operations prepared in accordance with
U.S. GAAP. The Company intends to continue to assess the potential
value of reporting non-GAAP results consistent with applicable
rules, regulations and guidance.
(2)
Adjustments included in 2023 relate to the gain on sale of our
Avian business, which was divested in 2022.
(3)
Amount included in 2023 relates to a final adjustment on the
termination of a Canadian pension plan. Amount included in 2022
relates to the sale of RMS Japan operations in October 2021 and a
reversal of an indemnification asset related to a prior
acquisition.
(4)
This amount relates to the recognition of deferred tax assets
expected to be utilized as a result of changes to the Company's
international financing structure.
CHARLES RIVER LABORATORIES
INTERNATIONAL, INC. SCHEDULE 6 RECONCILIATION
OF GAAP REVENUE GROWTH TO NON-GAAP REVENUE GROWTH, ORGANIC
(UNAUDITED) (1) Three Months Ended September
30, 2023 Total CRL RMS Segment DSA Segment
MS Segment Revenue growth, reported
3.8 %
3.7 %
7.2 %
(7.3)%
Increase due to foreign exchange
(1.4)%
(0.5)%
(1.5)%
(1.7)%
Contribution from acquisitions (2)
(0.2)%
— %
(0.4)%
— %
Impact of divestitures (3)
1.9 %
— %
— %
9.9 %
Non-GAAP revenue growth, organic (4)
4.1 %
3.2 %
5.3 %
0.9 %
Nine Months Ended September 30, 2023 Total CRL
RMS Segment DSA Segment MS Segment
Revenue growth, reported
8.3 %
9.9 %
13.3 %
(8.3)%
Decrease due to foreign exchange
0.3 %
1.0 %
0.1 %
— %
Contribution from acquisitions (2)
(0.7)%
(2.8)%
(0.3)%
— %
Impact of divestitures (3)
2.2 %
— %
— %
10.2 %
Non-GAAP revenue growth, organic (4)
10.1 %
8.1 %
13.1 %
1.9 %
(1)
Charles River management believes that supplementary non-GAAP
financial measures provide useful information to allow investors to
gain a meaningful understanding of our core operating results and
future prospects, without the effect of often-one-time charges and
other items which are outside our normal operations, consistent
with the manner in which management measures and forecasts the
Company’s performance. The supplementary non-GAAP financial
measures included are not meant to be considered superior to, or a
substitute for results of operations prepared in accordance with
U.S. GAAP. The Company intends to continue to assess the potential
value of reporting non-GAAP results consistent with applicable
rules, regulations and guidance.
(2)
The contribution from acquisitions reflects only completed
acquisitions.
(3)
The Company sold our Avian business on December 20, 2022. These
adjustments represent the revenue from these businesses for all
applicable periods in 2023 and 2022.
(4)
Organic revenue growth is defined as reported revenue growth
adjusted for acquisitions, divestitures, and foreign exchange.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231108042595/en/
Investor Contacts: Todd Spencer Corporate Vice President,
Investor Relations 781.222.6455 todd.spencer@crl.com
Media Contact: Amy Cianciaruso Corporate Vice President, Chief
Communications Officer 781.222.6168 amy.cianciaruso@crl.com
Charles River Laboratories (NYSE:CRL)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Charles River Laboratories (NYSE:CRL)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024